Immunomedics, Inc. (IMMU) Announces IMMU-132 is Active in Patients Refractory to Irinotecan
11/8/2013 9:40:54 AM
NEW YORK, Nov. 8, 2013 (GLOBE NEWSWIRE) -- Immunomedics, Inc. (Nasdaq:IMMU), a biopharmaceutical company primarily focused on the development of monoclonal antibody-based products for the targeted treatment of cancer, autoimmune and other serious diseases, today announced that some patients who had failed prior therapy with irinotecan or camptosar, both topoisomerase-1 inhibitors, responded to IMMU-132, the Company's lead antibody-drug conjugate (ADC) in clinical development for the treatment of patients with solid cancers.
Help employers find you! Check out all the jobs and post your resume.
comments powered by